Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹31 Cr
P/E Ratio
--
P/B Ratio
0.92
Industry P/E
37.33
Debt to Equity
0.52
ROE
1.45 %
ROCE
4.99 %
Div. Yield
0 %
Book Value
34.11
EPS
-0.04
CFO
₹22.47 Cr
EBITDA
₹49.76 Cr
Net Profit
₹10.00 Cr
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Concord Drugs
| -16.60 | -6.40 | -17.04 | -14.89 | 0.74 | 11.94 | -8.70 |
|
BSE Healthcare*
| -5.85 | 0.96 | -1.43 | 22.96 | 19.90 | 22.84 | 9.82 |
|
BSE Small Cap#
| -10.11 | 4.13 | -3.90 | 5.93 | 18.97 | 35.49 | 15.85 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Concord Drugs
| -32.81 | 83.47 | 1.24 | 46.01 | 53.18 | -33.63 | -26.50 |
|
BSE Small Cap
| 29.04 | 47.52 | -1.80 | 62.77 | 32.11 | -6.85 | -23.41 |
|
BSE Healthcare
| 43.09 | 36.97 | -12.10 | 20.87 | 61.45 | -3.55 | -5.89 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | P/E Ratio | ROE |
|---|---|---|---|---|
| 437.30 | 7,095.26 | 25.86 | 12.5 | |
| 5,201.00 | 8,712.93 | 36.83 | 43.77 | |
| 682.70 | 6,656.14 | 75.39 | 4.01 | |
| 663.00 | 6,139.88 | 22.78 | 12.68 |
No Review & Analysis are available.
Manufacture of pharmaceuticals, medicinal chemical and botanical products
Incorporated
1995
Chairman
S Nagi Reddy
Managing Director
S Nagi Reddy
Headquarters
Rangareddy Dist, Telangana
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Announcements
View Announcements
The total asset value of Concord Drugs Ltd stood at ₹ 73 Cr as on 31-Dec-24
The share price of Concord Drugs Ltd is ₹31.44 (BSE) as of 23-Apr-2025 IST. Concord Drugs Ltd has given a return of 0.74% in the last 3 years.
Concord Drugs Ltd has a market capitalisation of ₹ 31 Cr as on 23-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Concord Drugs Ltd is 0.92 times as on 23-Apr-2025, a 83% discount to its peers’ median range of 5.35 times.
Since, TTM earnings of Concord Drugs Ltd is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Concord Drugs Ltd and enter the required number of quantities and click on buy to purchase the shares of Concord Drugs Ltd.
Manufacture of pharmaceuticals, medicinal chemical and botanical products
The prominent promoters of Concord Drugs Ltd. are
| Name of promoters | Holding percentage |
|---|---|
|
NAGI REDDY SEELAM |
28.61%
|
|
MANOJ KUMAR REDDY SEELAM |
16.28%
|
|
SEELAM KONI REDDY |
9.51%
|
The chairman of the company is S Nagi Reddy, and the managing director is S Nagi Reddy.
There is no promoter pledging in Concord Drugs Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
8,680
|
|
|
7,005
|
|
|
6,570
|
|
|
6,016
|
| Concord Drugs Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
-0.12
|
|
Operating margin(%)
|
3.97
|
|
Net Margin(%)
|
-0.08
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Concord Drugs Ltd was ₹0 Cr.
₹0.44
(
